Skip to main content

Janus Henderson Investors — Portfolio, Page 2

Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.

227
Companies
$31.3B
Total invested
$160.4M
Avg. check
21
Industries
Biotechnology 22Health Care 13Life Science 12Biopharma 8Therapeutics 8Medical 8+15 more
Founder contacts

Verified emails & LinkedIn for founders across this portfolio.

jane@on●●●●●●●.com
linkedin.com/in/●●●●●●
Verified contacts, updated monthly
Get instant access →

Portfolio companies

Showing 2548 of 227
Element Biosciences
June 2026

Element Biosciences develops genomic sequencing and multiomics technologies used in drug discovery, and diagnostic applications.

Biotechnology · San DiegoSeries E
Elevation Oncology
June 2023

Elevation Oncology is a clinical-stage biopharmaceutical company focused on the development of precision medicines for patients.

Biopharma · New York$50.0M Post-IPO Equity
Jade Biosciences
June 2026

Jade Biosciences is developing transformative therapies to redefine the standard of care for inflammation and immunology indications.

Biopharma · Waltham$150.0M Post-IPO Equity
Entact Bio
June 2026

Entact Bio is a biotechnology company that is in the preclinical stages of developing medications to improve protein function.

Biopharma · Watertown$10.0M Venture - Series Unknown
Pyxis Oncology
June 2026

Pyxis Oncology is a biotechnology firm that develops antibody therapeutics intended to promote the body's immune response to cancer.

Biotechnology · Boston$50.0M Post-IPO Equity
4D Molecular Therapeutics
June 2026

4D Molecular Therapeutics designs, develops, and commercializes transformative gene therapeutic products for unmet medical conditions.

Biotechnology · Emeryville$200.0M Post-IPO Debt
Black Diamond Therapeutics
June 2023

Black Diamond Therapeutics is a medical company focused on analyzing genetically defined cancers.

Biotechnology · Cambridge$75.0M Post-IPO Equity
ALX Oncology
June 2026

ALX Oncology is a preclinical stage biotechnology company developing innovative immuno-oncology therapies for cancer.

Biopharma · San Francisco$10.0M Post-IPO Debt
Lycia Therapeutics
June 2026

Lycia Therapeutics is a biotechnology company that focuses on developing technology that utilizes lysosome-targeting chimeras.

Biotechnology · South San Francisco$75.0M Series D
Helus Pharma
June 2026

Helus Pharma is a biopharmaceutical company that develops psychedelic therapeutics for mental health conditions.

Biotechnology · Toronto$50.0M Post-IPO Equity
Entrada Therapeutics
June 2024

Entrada Therapeutics is a developer of novel therapeutics intended to treat devastating diseases.

Biotechnology · Boston$100.0M Post-IPO Equity
Definium Therapeutics
June 2026

Definium Therapeutics provides psychedelic-inspired medicines and therapies for substance abuse disorders and other mental illnesses.

Biotechnology · New York$805.0M Post-IPO Equity
SmartMedia Technologies
June 2026

SmartMedia Technologies is the Enterprise SaaS Web3 platform the future is being built on.

Blockchain · CarbondaleUndisclosed
IGM Biosciences
June 2023

IGM Biosciences is a biotechnology company that develops medicine for people with infectious infections, autoimmune diseases, and cancer.

Biotechnology · Mountain View$107.3M Post-IPO Equity
Triveni Bio
June 2026

Triveni Bio is a biotechnology company that develops antibody-based therapeutics for immunological and inflammatory diseases.

Biotechnology · Watertown$65.0M Series C
Mereo Biopharma
June 2024

Mereo is a new UK-based speciality biopharmaceutical company.

Biopharma · London$50.0M Post-IPO Equity
Oak hill bio
June 2026

Oak hill bio is a clinical-stage rare disease therapeutics company developing life-changing medicines.

Biotechnology · Altrincham$32.5M Series A
Enliven Therapeutics
June 2026

Enliven Therapeutics is a precision oncology company developing small molecule therapies to extend and improve patient lives.

Biotechnology · Boulder$460.0M Post-IPO Equity
Parabilis Medicines
June 2026

Parabilis Medicines is a Grupo Bugio is a biopharmaceutical firm that specializes in creating medicines.

Biopharma · Cambridge$75.0M Post-IPO Equity
Shattuck Labs
June 2026

Shattuck Labs is a biotechnology company that provides novel class biologic medicines for the treatment of cancer and autoimmune disease.

Biopharma · Austin$75.0M Post-IPO Equity
Artiva Biotherapeutics
May 2026

Artiva Biotherapeutics is a biotech company focused on developing and commercializing allogeneic natural killer (NK) cell therapies.

Biotechnology · San Diego$300.0M Post-IPO Equity
Equillium
March 2026

Equillium is a biotechnology company that develops products for autoimmune and inflammatory disorders with an unmet medical need.

Biopharma · La Jolla$35.0M Post Ipo Equity
Longeveron
March 2026

Longeveron is a biotechnology company that focuses on developing cellular therapies for chronic aging-related and life-threatening diseases.

Biotechnology · Miami$30.0M Post Ipo Equity
Solid Biosciences
March 2026

Solid Biosciences is a life science company that conducts research for the treatment of Duchenne muscular dystrophy.

Biotechnology · Charlestown$240.0M Post Ipo Equity

Where Janus Henderson Investors invests

Biotechnology22
Health Care13
Life Science12
Biopharma8
Therapeutics8
Medical8

About Janus Henderson Investors's portfolio

How many companies has Janus Henderson Investors invested in?

Janus Henderson Investors has invested in 227 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.

What industries does Janus Henderson Investors invest in?

Janus Henderson Investors's top investment sectors include Biotechnology, Health Care, Life Science, Biopharma, Therapeutics. The firm invests across 21 different industry categories.

What is Janus Henderson Investors's largest investment?

Among tracked funding rounds, Definium Therapeutics received $805.0M in a Post-IPO Equity round. Janus Henderson Investors's total known invested capital is $31.3B.

What is the average investment size for Janus Henderson Investors?

Janus Henderson Investors's average investment size is $160.4M across its portfolio of 227 companies.

What are Janus Henderson Investors's most recent investments?

Recent Janus Henderson Investors portfolio additions include Element Biosciences, Elevation Oncology, Jade Biosciences, Entact Bio, Pyxis Oncology. These companies were founded in 2020 or later.

Reach the founders behind these 227 companies
Verified emails and LinkedIn profiles, updated monthly.
Get instant access →